The receptor tyrosine kinase ERBB2 is overexpressed in 15–20% of breast tumors and increased ERBB2 is capable of enhancing cancer cell proliferation and invasion, which is associated with a poor prognosis for overall survival (Murthy et al., 2016; Ethier et al., 2021). Here, NTRK1 is linked to cancer.